RxDoctor Payments DataLook up a doctor →

Jonathan Kruger, MD

Rheumatology · Fayetteville, ARNPI 1093031940

Payments from drug & device makers

$11,664in general payments, 2019–2025

Across 634 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AbbVie$2K
  • UCB, Inc.$988
  • Pfizer$893
  • Johnson & Johnson$678
  • Novartis$674
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$11,57499%
  • Education$891%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,664 in reported general payments places this provider in the 60th percentile of 48 rheumatology providers in Arkansas.

See all rheumatology providers in Arkansas

Medicare billing

Part B allowed, 2024
$1,313,808
Medicare patients
588
Services billed
84,887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept95$713,429
Humira(Cf) PenAdalimumab32$221,988
Gamunex-CImmune Globul G/Gly/Iga Avg 4624$193,835
Xeljanz XrTofacitinib Citrate29$176,214
RinvoqUpadacitinib17$114,303
Orencia ClickjectAbatacept12$111,331
KevzaraSarilumab14$89,077
Cosentyx (2 Syringes)Secukinumab13$88,418
MethotrexateMethotrexate Sodium431$9,181
Mycophenolate Mofetil73$6,841
Hydroxychloroquine Sulfate130$6,676
Leflunomide146$6,366
Cevimeline Hcl34$4,271
Sulfasalazine DrSulfasalazine62$2,274
Celecoxib70$1,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$2,090$114,30317 claims
SanofiKevzara$72$89,07714 claims
NovartisCosentyx (2 Syringes)$674$88,41813 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$19$6,84173 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 48 rheumatology providers in Arkansas.

Other rheumatology in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →